EC finalizes deal for 300 million doses of Pfizer and BioNTech vaccine

11 November 2020

In timely fashion, a deal has been announced for the European Commission (EC) to be supplied with 200 million doses of the Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) mRNA-based vaccine candidate against COVID-19.

Only on Monday, the two-dose vaccine, presently referred to as BNT162b2, showed more than 90% efficacy in a Phase III trial read-out.

"Today’s finalized supply agreement with the EC represents the largest initial order of vaccine doses for Pfizer and BioNTech to date"The deal, which marks the conclusion of exploratory talks that began in September, will see European Union (EU) member states supplied with 200 million doses, with an option for the EC to request an additional 100 million more doses. Deliveries are anticipated to start by the end of 2020, subject to clinical success and regulatory authorization.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK